2017 Fiscal Year Final Research Report
New oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial.
| Project/Area Number |
15K20211
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | アレルギー性鼻炎 / スギ花粉症 / 経口免疫療法 |
|---|
| Outline of Final Research Achievements |
The prevalence of Japanese cedar pollinosis (JCP) has been increasing, and is currently around 30%. JCP is now called a part of Japanese national disease, but until now there has been no treatment to improve the allergy constitution in a short term regimen. Therefore, we developed a new oral immunotherapy to take antigen-galactomannan conjugate capsules using intestinal immunity. In addition, the treatment period is very short for about 2 months before and after the pollen is scattered. In this RCT, OIT with antigen-galactomannan conjugate was safe and approved to reduce anti-allergic medicine by about 60% compared to standard treatment.In the near future, there is a possibility that it will lead to a new immunotherapy to improve the allergy constitution.
|
| Free Research Field |
耳鼻咽喉科
|
